119 related articles for article (PubMed ID: 7140004)
1. The protein binding and elimination of methotrexate after intravenous infusions in cancer patients.
Paxton JW
Clin Exp Pharmacol Physiol; 1982; 9(3):225-34. PubMed ID: 7140004
[TBL] [Abstract][Full Text] [Related]
2. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.
Evans WE; Hutson PR; Stewart CF; Cairnes DA; Bowman WP; Rivera G; Crom WR
Clin Pharmacol Ther; 1983 Mar; 33(3):301-7. PubMed ID: 6600662
[TBL] [Abstract][Full Text] [Related]
3. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
4. Test dose for predicting high-dose methotrexate infusions.
Kerr IG; Jolivet J; Collins JM; Drake JC; Chabner BA
Clin Pharmacol Ther; 1983 Jan; 33(1):44-51. PubMed ID: 6848298
[TBL] [Abstract][Full Text] [Related]
5. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
Lokich JJ; Curt G
Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and toxicity of frequent intermediate dose methotrexate infusions.
Parker RI; Forman EN; Krumm KF; Abeel MJ; Martin HF
Ther Drug Monit; 1986; 8(4):393-9. PubMed ID: 3469802
[TBL] [Abstract][Full Text] [Related]
7. Prolongation and enhancement of serum methotrexate concentrations by probenecid.
Aherne GW; Piall E; Marks V; Mould G; White WF
Br Med J; 1978 Apr; 1(6120):1097-9. PubMed ID: 638616
[TBL] [Abstract][Full Text] [Related]
8. Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.
Benz C; DeGregorio M; Saks S; Sambol N; Holleran W; Ignoffo R; Lewis B; Cadman E
Cancer Res; 1985 Jul; 45(7):3354-8. PubMed ID: 4005858
[TBL] [Abstract][Full Text] [Related]
9. Prolonged methotrexate infusions in children with acute leukemia in relapse and in remission and with medulloblastoma. Pharmacokinetics, toxicity and clinical results.
Janka GE; Mack R; Helmig M; Haas RJ; Bidlingmaier F
Oncology; 1984; 41(4):225-32. PubMed ID: 6589560
[TBL] [Abstract][Full Text] [Related]
10. High-dose methotrexate: preliminary evaluation of a pharmacokinetic approach.
Monjanel S; Rigault JP; Cano JP; Carcassonne Y; Favre R
Cancer Chemother Pharmacol; 1979; 3(3):189-96. PubMed ID: 527209
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate in rabbits.
Iven H; Brasch H; Engster J
Cancer Chemother Pharmacol; 1985; 15(2):115-20. PubMed ID: 4017160
[TBL] [Abstract][Full Text] [Related]
12. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
[TBL] [Abstract][Full Text] [Related]
13. Lack of correlation between methotrexate concentrations in serum, saliva and sweat after 24 h methotrexate infusions.
Schrøder H; Jensen KB; Brandsborg M
Br J Clin Pharmacol; 1987 Oct; 24(4):537-41. PubMed ID: 3689633
[TBL] [Abstract][Full Text] [Related]
14. Long-duration intracavitary infusion of methotrexate with systemic leucovorin protection in patients with malignant effusions.
Howell SB; Chu BB; Wung WE; Metha BM; Mendelsohn J
J Clin Invest; 1981 Apr; 67(4):1161-70. PubMed ID: 6970753
[TBL] [Abstract][Full Text] [Related]
15. Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.
Chen ML; Chiou WL
J Pharmacokinet Biopharm; 1983 Oct; 11(5):515-27. PubMed ID: 6668557
[TBL] [Abstract][Full Text] [Related]
16. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy.
Schwartz S; Borner K; Müller K; Martus P; Fischer L; Korfel A; Auton T; Thiel E
Oncologist; 2007 Nov; 12(11):1299-308. PubMed ID: 18055849
[TBL] [Abstract][Full Text] [Related]
17. Comparison of linear and tapered intravenous infusion of methotrexate in oncochemotherapy. A theoretical approach.
Termond EF; Zonnenberg B; Winograd B; Oosterbaan MJ; Van der Kleijn E; Vree TB
Pharm Weekbl Sci; 1985 Aug; 7(4):158-62. PubMed ID: 4047914
[TBL] [Abstract][Full Text] [Related]
18. High-performance liquid chromatographic and enzyme-inhibition assays of methotrexate concentrations in serum from patients receiving high-dose therapy: tight binding of some methotrexate to a protein that could be dihydrofolate reductase.
Iven H; Bartels H
Cancer Treat Rep; 1985; 69(7-8):825-32. PubMed ID: 4016793
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic study of methotrexate, folinic acid and their serum metabolites in children treated with high-dose methotrexate and leucovorin rescue.
Wolfrom C; Hepp R; Hartmann R; Breithaupt H; Henze G
Eur J Clin Pharmacol; 1990; 39(4):377-83. PubMed ID: 2076721
[TBL] [Abstract][Full Text] [Related]
20. Potential for methotrexate exposure through contamination during parenteral use as an immunosuppressant.
Wong LS; Tymms KE; Buckley NA
Intern Med J; 2009 Jun; 39(6):379-83. PubMed ID: 19580617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
